Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial
Abstract Background Efficacy and tolerance of anakinra (ANK) in the treatment of giant cell arteritis (GCA) need to be assessed. Methods This phase 3 study (NCT02902731) was a prospective multicenter, randomized, double-blind, placebo-controlled trial conducted over a 52-week period. GCA patients we...
Saved in:
| Main Authors: | Hubert de Boysson, Kim Heang Ly, Loïk Geffray, Thomas Quemeneur, Eric Liozon, Holy Bezanahary, Noémie Le Gouellec, Alexandra Audemard, Anael Dumont, Samuel Deshayes, Jonathan Boutemy, Gwénola Maigné, Nicolas Martin Silva, Audrey Sultan, Brigitte Le Mauff, Gauthier Petit, Jean-Jacques Parienti, Achille Aouba |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-025-03493-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of anakinra in a patient with gout and long-term follow-up of rheumatoid arthritis
by: E. V. Cheremushkina, et al.
Published: (2023-07-01) -
The use of Anakinra in a patient with a combination of two autoinflammatory diseases: Familial Mediterranean fever and gout
by: M. S. Eliseev, et al.
Published: (2023-04-01) -
The use of Anakinra in treatment of calcium pyrophosphate crystal deposition disease: Analysis of own experience and a literature review
by: M. S. Eliseev, et al.
Published: (2022-12-01) -
The Comparative Effects of Anakinra and Tocilizumab on Inflammation and Cerebral Vasospasm in an Experimental Subarachnoid Hemorrhage Model
by: Güven Kılıç, et al.
Published: (2024-12-01) -
The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)
by: E. L. Nasonov, et al.
Published: (2022-07-01)